Windtree Therapeutics, Inc. (WINT)
OTCMKTS · Delayed Price · Currency is USD
0.0551
-0.0048 (-8.01%)
At close: Dec 11, 2025
Windtree Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
1.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Windtree Therapeutics News
- 8 days ago - Windtree Therapeutics (WINT) to Acquire CommLoan: A Strategic Move - GuruFocus
- 24 days ago - Windtree Therapeutics (WINT) Eyes Potential Milestone Payments from License Agreement - GuruFocus
- 4 weeks ago - Windtree Therapeutics (WINT) Secures $7.5 Million in Strategic Agreement - GuruFocus
- 3 months ago - Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at ... - GuruFocus
- 4 months ago - BNB treasury firm plunges 77% after Nasdaq delisting notice - Cointelegraph
- 4 months ago - Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 - GlobeNewsWire
- 4 months ago - Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption - GlobeNewsWire
- 4 months ago - BNB Rebounds to $780 After $520M Windtree Buy Commitment, Shows Signs of Stabilizing - CoinDesk